U.S. Markets closed

IceCure Medical Ltd (ICUSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.23000.0000 (0.00%)
At close: 9:32AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2300
Open0.2300
BidN/A x N/A
AskN/A x N/A
Day's Range0.2300 - 0.2300
52 Week Range0.1300 - 0.3100
Volume10,000
Avg. Volume1,581
Market Cap30.714M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
    PR Newswire

    IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

    IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that it has expanded its strategic partnership with Terumo Corporation (Tokyo: 4543) (TRUMY: OTC US), a leading Japanese medical devices company with a global footprint. The expanded partnership reflects the ongoing success of the initial agreement, which was signed in September 2019, and included distribution rights in Japan and Singapore. The new multi-million dollar agreement, which is expected to be finalized by the end of the year, will grant Terumo exclusive rights to distribute IceCure's products in Thailand for six years, with an option to extend the agreement for an additional six years.

  • IceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million
    PR Newswire

    IceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million

    IceCure Medical (Tel Aviv: ICCM) a leading medical device company that markets a non-surgical Liquid Nitrogen (LN2) cryoablation technology to destroy benign and cancerous tumors, today announced that it has completed a NIS 20.7 million equity offering, which was oversubscribed. IceCure Medical believes that the proceeds it received in the offering, when combined with the cash and cash equivalents it had on June 30, 2020, will enable the Company to effectively execute on its growth strategy.

  • IceCure's Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India
    PR Newswire

    IceCure's Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India

    IceCure Medical (TA: ESCM), a developer and marketer of minimally-invasive cryoablation therapies for the women's health and interventional oncology markets, today announced that a license has been granted by the Indian regulatory authority, CDSCO (Central Drugs Standard Control Organisation). The approval is for the sale and marketing of IceCure's ProSense® system and associated products for the destruction of tissue by cryoablation in extensive indications, including breast, lung, bone, kidney cancer and more.